UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1116-19
Program Prior Authorization/Notification
Medication Xeljanz®/Xeljanz® XR/Xeljanz® Oral Solution (tofacitinib)
P&T Approval Date 11/2012, 2/2013, 2/2014, 2/2015, 3/2016, 3/2017, 2/2018, 7/2018,
7/2019, 9/2019, 2/2020, 11/2020, 11/2021, 2/2022, 2/2023, 7/2023,
9/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Xeljanz/Xeljanz XR (tofacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment
of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic
arthritis, ankylosing spondylitis and moderately to severely active ulcerative colitis, who have
had an inadequate response or intolerance to one or more TNF blockers. Xeljanz/Xeljanz Oral
Solution is indicated for the treatment of active polyarticular course juvenile idiopathic
arthritis in patients 2 years of age and older who have had an inadequate response or
intolerance to one or more TNF blockers.
Limitations of Use:
The use of Xeljanz/Xeljanz XR/Xeljanz Oral Solution in combination with biologic
DMARDs, biologic therapies for UC or potent immunosuppressants such as azathioprine and
cyclosporine is not recommended.
2. Coverage Criteriaa:
A. Rheumatoid Arthritis (RA)
1. Initial Authorization
a. Xeljanz or Xeljanz XR will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active RA
-AND-
(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor
-AND-
(3) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the
following:
(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq
(upadacitinib), Olumiant (baricitinib)]
(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)
© 2024 UnitedHealthcare Services, Inc.
1
Authorization will be issued for 12 months.
2. Reauthorization
a. Xeljanz or Xeljanz XR will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Xeljanz or Xeljanz XR therapy
-AND-
(2) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the
following:
(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq
(upadacitinib), Olumiant (baricitinib)]
(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)
Authorization will be issued for 12 months.
B. Psoriatic Arthritis (PsA)
1. Initial Authorization
a. Xeljanz or Xeljanz XR will be approved based on all of the following criteria:
(1) Diagnosis of active PsA
-AND-
(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor
-AND-
(3) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the
following:
(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx
(secukinumab), Taltz (ixekizumab), Rinvoq (upadacitinib), Olumiant
(baricitinib), Otezla (apremilast)]
(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
2
2. Reauthorization
a. Xeljanz or Xeljanz XR will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Xeljanz or Xeljanz XR therapy
-AND-
(2) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the
following:
(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx
(secukinumab), Taltz (ixekizumab), Rinvoq (upadacitinib), Olumiant
(baricitinib), Otezla (apremilast)]
(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)
Authorization will be issued for 12 months.
C. Ulcerative Colitis (UC)
1. Initial Authorization
a. Xeljanz or Xeljanz XR will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active UC
-AND-
(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor
-AND-
(3) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the
following:
(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq
(upadacitinib), Olumiant (baricitinib), Stelara (ustekinumab), Skyrizi
(risankizumab)]
(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate
mofetil)
Authorization will be issued for 12 months.
2. Reauthorization
a. Xeljanz or Xeljanz XR will be approved based on both of the following criteria:
© 2024 UnitedHealthcare Services, Inc.
3
(1) Documentation of positive clinical response to Xeljanz or Xeljanz XR therapy
-AND-
(2) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the
following:
(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq
(upadacitinib), Olumiant (baricitinib), Stelara (ustekinumab), Skyrizi
(risankizumab)]
(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate
mofetil)
Authorization will be issued for 12 months.
D. Ankylosing Spondylitis
1. Initial Authorization
a. Xeljanz or Xeljanz XR will be approved based on all of the following criteria:
(1) Diagnosis of active ankylosing spondylitis
-AND-
(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor
-AND-
(3) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the
following:
(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq
(upadacitinib), Olumiant (baricitinib)]
(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate
mofetil)
Authorization will be issued for 12 months.
2. Reauthorization
a. Xeljanz or Xeljanz XR will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Xeljanz or Xeljanz XR therapy
-AND-
(2) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the
© 2024 UnitedHealthcare Services, Inc.
4
following:
(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq
(upadacitinib), Olumiant (baricitinib)]
(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate
mofetil)
Authorization will be issued for 12 months.
E. Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)
1. Initial Authorization
a. Xeljanz or Xeljanz Oral Solution will be approved based on both of the following
criteria:
(1) Diagnosis of active polyarticular course juvenile idiopathic arthritis
-AND-
(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor
-AND-
(3) Patient is not receiving Xeljanz or Xeljanz Oral Solution in combination with
either of the following:
(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Olumiant
(baricitinib), Rinvoq (upadacitinib)]
(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate
mofetil)
Authorization will be issued for 12 months.
2. Reauthorization
a. Xeljanz or Xeljanz Oral Solution will be approved based on both of the following
criteria:
(1) Documentation of positive clinical response to Xeljanz or Xeljanz Oral Solution
therapy
-AND-
(2) Patient is not receiving Xeljanz or Xeljanz Oral Solution in combination with
either of the following:
(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
© 2024 UnitedHealthcare Services, Inc.
5
Simponi (golimumab), Orencia (abatacept), adalimumab, Olumiant
(baricitinib), Rinvoq (upadacitinib)]
(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate
mofetil)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits and/or Step Therapy may be in place.
4. References:
1. Xeljanz/Xeljanz XR/Xeljanz Oral Solution [package insert]. New York, NY: Pfizer Labs;
May 2024.
Program Prior Authorization/Notification – Xeljanz/Xeljanz XR/Xeljanz Oral
Solution (tofacitinib)
Change Control
2/2014 Changed methotrexate failure criterion to standard verbiage.
Reauthorization criteria revised to include concomitant therapy criteria.
Extended reauthorization duration to 24 months.
9/2014 Administrative change - Tried/Failed exemption for State of New Jersey
removed.
2/2015 Annual review with no change to coverage criteria. Minor reformatting.
Updated clinical rules, background and references.
3/2016 Annual review with minor formatting changes to the coverage criteria
with no changes to the clinical intent. Added Xeljanz XR to criteria.
Updated reference.
3/2017 Annual review with no change to coverage criteria. Updated
references.
3/2018 Administrative change to adjust Oxford effective date.
2/2018 Added psoriatic arthritis to the coverage rationale. Updated references.
7/2018 Added ulcerative colitis to the coverage rationale. Updated references.
7/2019 Annual review with no changes to the coverage criteria. Updated
background.
9/2019 Updated coverage rationale for ulcerative colitis to align with
prescribing information. Updated background and references.
2/2020 Added Xeljanz XR to the ulcerative colitis section due to expanded
indication for use. Updated background and references.
11/2020 Updated background and criteria due to new indication for polyarticular
juvenile idiopathic arthritis. Changed all reauthorization durations to 12
© 2024 UnitedHealthcare Services, Inc.
6
months and removed concomitant use with PDE4 inhibitor in UC
section to align with related programs. Updated references.
11/2021 Annual review. Added Rinvoq as example of JAK inhibitor in RA
section. Updated background and reference.
2/2022 Added step through a TNF inhibitor for RA, PsA and pcJIA per updated
label. Updated language in step through TNF inhibitor for UC. Added
coverage criteria for new indication, ankylosing spondylitis. Updated
background and references.
2/2023 Annual review. Updated listed examples from Humira to adalimumab.
Updated reference. Added state mandate footnote.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
9/2023 Updated examples. No change to coverage criteria.
10/2024 Annual review with no change to criteria. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
7